Showing results (991-1000 of 5,692) with videos related to
Sort By:
Pageof 570
The Oncologist|August 9, 2019
Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) DataMarta B Bean, Yuan Liu, Renjain Jiang, et al.The Oncologist|August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF AlterationsAditya Bardia, Mrinal Gounder, Jordi Rodon, et al.The Oncologist|August 23, 2019
Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast CancerQianyi Lu, Wen Xia, Kaping Lee, et al.The Oncologist|April 3, 2019
Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric CancerAnuradha Vasista, Martin Stockler, Andrew Martin, et al.The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.The Oncologist|August 25, 2019
Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid MalignanciesYuefeng Wang, Manjari Pandey, Matthew T BalloThe Oncologist|August 25, 2019
Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial CancerArthur Winer, Pooja Ghatalia, Nicole Bubes, et al.The Oncologist|July 24, 2019
Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung CancerKoichi Takayama, Masao Ichiki, Shoji Tokunaga, et al.The Oncologist|July 20, 2019
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?Omer Ben-Aharon, Racheli Magnezi, Moshe Leshno, et al.The Oncologist|October 25, 2018
Conflict of Interest: An Ethical Firestorm with Consequences for Cancer ResearchBruce A Chabner, Susan E BatesPageof 570